Cat. No.: HY-12871B

Atuveciclib

(Synonyms: BAY-1143572)

10 Cited Publications

Customer Review

Based on 10 publication(s) in Google Scholar

Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb/CDK9 inhibitor. Atuveciclib (BAY-1143572) inhibits CDK9/CycT1 with an IC₅₀ of 13 nM.

For research use only. We do not sell to patients.

Purity: 99.75%
CAS No.: 2923012-24-0
Formula: C₁₈H₁₈FN₅O₂S
Molecular Weight:387.43

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Atuveciclib Chemical Structure

CAS No.: 2923012-24-0

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (10)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb/CDK9 inhibitor. Atuveciclib (BAY-1143572) inhibits CDK9/CycT1 with an IC₅₀ of 13 nM^[1].

IC₅₀ & Target^[1]

CDK9/CycT1

13 nM (IC₅₀)

CDK9/CycT1(h)

6 nM (IC₅₀)

CDK3/CycE(h)

890 nM (IC₅₀)

CDK2/CycE(h)

1000 nM (IC₅₀)

CDK1/CycB(h)

1100 nM (IC₅₀)

CDK5/p35(h)

1600 nM (IC₅₀)

All CDK Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	IC₅₀	0.34 μM Compound: BAY-1143572	Antiproliferative activity against human A-431 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human A-431 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 36332552]
A549	IC₅₀	3.29 μM Compound: BAY-1143572	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 33338869]
B16	IC₅₀	1.47 μM Compound: BAY-1143572	Antiproliferative activity against mouse B16 cells incubated for 72 hrs by MTT assay Antiproliferative activity against mouse B16 cells incubated for 72 hrs by MTT assay	[PMID: 33338869]
BT-549	IC₅₀	2.01 μM Compound: (+)-BAY-1143572	Antiproliferative activity against human BT-549 cells assessed as inhibition of cell growth Antiproliferative activity against human BT-549 cells assessed as inhibition of cell growth	[PMID: 37837671]
HCT-116	IC₅₀	0.26 μM Compound: BAY-1143572	Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 36332552]
HCT-116	IC₅₀	2.94 μM Compound: BAY-1143572	Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by MTT assay	[PMID: 33338869]
HeLa	IC₅₀	1500 nM Compound: 50; BAY-1143572	Antiproliferative activity against human HeLa cells incubated for 96 hrs by crystal violet staining assay Antiproliferative activity against human HeLa cells incubated for 96 hrs by crystal violet staining assay	[PMID: 32870008]
HepG2	IC₅₀	2.7 μM Compound: BAY-1143572	Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 33338869]
L02	IC₅₀	2.55 μM Compound: BAY-1143572	Antiproliferative activity against human L02 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human L02 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 36332552]
MCF7	IC₅₀	5.52 μM Compound: BAY-1143572	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 33338869]
MDA-MB-231	IC₅₀	1.32 μM Compound: (+)-BAY-1143572	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth	[PMID: 37837671]
MDA-MB-436	IC₅₀	0.63 μM Compound: (+)-BAY-1143572	Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell growth Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell growth	[PMID: 37837671]
MOLM-13	IC₅₀	0.2 μM Compound: BAY-1143572	Antiproliferative activity against human MOLM-13 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MOLM-13 cells incubated for 72 hrs by MTT assay	[PMID: 33338869]
MOLM-13	IC₅₀	310 nM Compound: 3	Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell viability incubated for 96 hrs by Cell Titer-Glo reagent assay Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell viability incubated for 96 hrs by Cell Titer-Glo reagent assay	[PMID: 38564299]
MV4-11	IC₅₀	0.56 μM Compound: BAY-1143572	Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MV4-11 cells incubated for 72 hrs by MTT assay	[PMID: 33338869]
NCI-H1975	IC₅₀	0.72 μM Compound: BAY-1143572	Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 36332552]
NCI-H1975	IC₅₀	1.08 μM Compound: BAY1143572	Antiproliferative activity against human Osimertinib-resistant NCI-H1975 cell incubated for 72 hrs by MTT assay Antiproliferative activity against human Osimertinib-resistant NCI-H1975 cell incubated for 72 hrs by MTT assay	[PMID: 37870244]
PANC-1	IC₅₀	0.11 μM Compound: BAY-1143572	Antiproliferative activity against human PANC-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human PANC-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 36332552]
Sf9	IC₅₀	1000 nM Compound: BAY-1143572	Inhibition of recombinant GST-tagged human CDK2/cyclin-E expressed in sf9 cels using biotin-Ttds-YISPLKSPYKISEG as substrate preincubated for 15 mins followed by substrate addition and measured after 25 mins in presence of ATP by TR-FRET assay Inhibition of recombinant GST-tagged human CDK2/cyclin-E expressed in sf9 cels using biotin-Ttds-YISPLKSPYKISEG as substrate preincubated for 15 mins followed by substrate addition and measured after 25 mins in presence of ATP by TR-FRET assay	[PMID: 31238183]

In Vitro

Positive transcription elongation factor b (PTEFb) is a heterodimer of CDK9 and one of four cyclin partners, cyclin T1, cyclin K, cyclin T2a or cyclin T2b. Atuveciclib (BAY-1143572) demonstrates potent antiproliferative activity against HeLa cells (IC₅₀=920 nM) and MOLM-13 cells (IC₅₀=310 nM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In vivo efficacy studies in the MOLM-13 xenograft model in mice, Atuveciclib (BAY-1143572) demonstrates great potency and high antitumor efficacy. Daily administration of Atuveciclib (BAY-1143572) at 6.25 or 12.5 mg/kg results in a dose-dependent antitumor efficacy with a treatment-to-control (T/C) ratio of 0.64 and 0.49, respectively (p<0.001). In a separate experiment with a higher daily dose of 20 or 25 mg/kg Atuveciclib (BAY-1143572), antitumor efficacy with a T/C ratio of 0.41 and 0.31, respectively, is observed (p<0.001). The 25 mg/kg once daily dose is the maximum tolerated dose in nude mice. Furthermore, Atuveciclib (BAY-1143572) administered at 25 or 35 mg/kg, three days on / two days off, results in a T/C ratio of 0.33 and 0.20, respectively (p<0.001). Treatment with Atuveciclib (BAY-1143572) is well-tolerated, as demonstrated by less than 10 % mean body weight reduction throughout the study. In an in vivo pharmacokinetic study in rats, Atuveciclib (BAY-1143572) shows low blood clearance (CL_b 1.1 L/kg per hour)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 2923012-24-0
Appearance Solid
Molecular Weight 387.43
Formula C₁₈H₁₈FN₅O₂S
Color White to off-white
SMILES

N=[S@](CC1=CC(NC2=NC(C3=CC=C(F)C=C3OC)=NC=N2)=CC=C1)(C)=O
Synonyms

BAY-1143572
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (10)

All

Sort by:

Journal Impact Factor

Nature

Rapid unleashing of macrophage efferocytic capacity via transcriptional pause release. [Abstract]

2024 Apr;628(8007):408-415. PMID: 38480883
Cell Death Dis

CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells. [Abstract]

2020 Sep 15;11(9):754. PMID: 32934219
Cell Rep

Super Elongation Complex as a Targetable Dependency in Diffuse Midline Glioma. [Abstract]

2020 Apr 7;31(1):107485. PMID: 32268092
Breast Cancer Res

Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors. [Abstract]

2023 May 5;25(1):51. PMID: 37147730
Breast Cancer Res

A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy. [Abstract]

2019 Jul 1;21(1):77. PMID: 31262335
Commun Biol

A genome-scale CRISPR Cas9 dropout screen identifies synthetically lethal targets in SRC-3 inhibited cancer cells. [Abstract]

2021 Mar 25;4(1):399. PMID: 33767353
Biomolecules

Crinamine Induces Apoptosis and Inhibits Proliferation, Migration, and Angiogenesis in Cervical Cancer SiHa Cells. [Abstract]

2019 Sep 16;9(9):494. PMID: 31527550
Anticancer Res

The Novel, Orally Bioavailable CDK9 Inhibitor Atuveciclib Sensitises Pancreatic Cancer Cells to TRAIL-induced Cell Death. [Abstract]

2021 Dec;41(12):5973-5985. PMID: 34848451
Res Sq

2025 Dec 18.
Ulm University

2024 Apr 5.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (258.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5811 mL

12.9056 mL

25.8111 mL

5 mM

0.5162 mL

2.5811 mL

5.1622 mL

10 mM

0.2581 mL

1.2906 mL

2.5811 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass

Concentration

Volume

Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.45 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.45 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage
mg/kg
Animal Weight (Per Animal)
g
Dosing Volume (Per Animal)
μL
Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[1]

HeLa human cervical tumor cells (CCL-2) and MOLM-13 human acute myeloid leukemia cells (ACC 554) are propagated under the suggested growth conditions in a humidified 37°C incubator. Proliferation assays are conducted in 96-well plates at densities of 3000 (HeLa) and 5000 (MOLM-13) cells per well in the growth medium containing 10 % fetal calf serum (FCS). Cells are treated in quadruplicate with serial dilutions of test compounds (e.g., Atuveciclib (BAY-1143572)) for 96 h. Relative cell numbers are quantified by crystal violet staining (HeLa) or CellTitre-Glo Luminescent Cell Viability Assay (MOLM-13). IC₅₀ values are determined by means of a four-parameter fit on measurement data which are normalized to vehicle (DMSO) treated cells (=100 %) and measurement readings taken immediately before compound exposure (=0 %)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice and Rats^[1]
For the acute myeloid leukemia (AML) mouse model, 2×10⁶ MOLM-13 human AML cells are inoculated subcutaneously to the left flank of female NMRI nu/nu mice (18-21 g, 5-6 weeks). For the AML model in rats, 2×10⁶ MV4-11 human AML cells are inoculated subcutaneously to the left flank of female athymic nude rats (160-200 g, 5-6 weeks). Animals are stratified into treatment and control groups (n=8-13/group for mice, n=12/group for rats) based on primary tumor size. Treatments are started 3-13 days after tumor cell inoculation when the average tumor sizes are 23-38 mm² and 43 mm² for mice and rats, respectively. The 20 and 25 mg/kg once daily dose is for nude mice. Furthermore, Atuveciclib (BAY-1143572) administered at 25 or 35 mg/kg, three days on/two days off. BAY-1143572 is administered daily oral administration of Atuveciclib (BAY-1143572) at 12 mg/kg for rats. Unless otherwise indicated, all treatments are administered orally (p.o.) and are continued until the end of the experiment. Body weight and tumor areas (longest diameter multiplied by its perpendicular) measured by caliper are determined at least twice weekly. T/C ratios are calculated by dividing the mean tumor area of the treatment group by the mean tumor area of the vehicle group at the time point when the vehicle group is sacrificed^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Lücking U, et al. Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer. ChemMedChem. 2017 Nov 8;12(21):1776-1793. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5811 mL	12.9056 mL	25.8111 mL	64.5278 mL
	5 mM	0.5162 mL	2.5811 mL	5.1622 mL	12.9056 mL
	10 mM	0.2581 mL	1.2906 mL	2.5811 mL	6.4528 mL
	15 mM	0.1721 mL	0.8604 mL	1.7207 mL	4.3019 mL
	20 mM	0.1291 mL	0.6453 mL	1.2906 mL	3.2264 mL
	25 mM	0.1032 mL	0.5162 mL	1.0324 mL	2.5811 mL
	30 mM	0.0860 mL	0.4302 mL	0.8604 mL	2.1509 mL
	40 mM	0.0645 mL	0.3226 mL	0.6453 mL	1.6132 mL
	50 mM	0.0516 mL	0.2581 mL	0.5162 mL	1.2906 mL
	60 mM	0.0430 mL	0.2151 mL	0.4302 mL	1.0755 mL
	80 mM	0.0323 mL	0.1613 mL	0.3226 mL	0.8066 mL
	100 mM	0.0258 mL	0.1291 mL	0.2581 mL	0.6453 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Atuveciclib

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Anti-Breast Cancer Compound Library

Anti-Blood Cancer Compound Library

Cancer Stem Cells Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) Atuveciclib

All CDK Isoforms

Biological Activity

Chemical Information

Publications (10)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Atuveciclib

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Anti-Breast Cancer Compound Library

Anti-Blood Cancer Compound Library

Cancer Stem Cells Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) Atuveciclib

All CDK Isoforms

Biological Activity

Chemical Information

Publications (10)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Atuveciclib Related Classifications

Cat. No.: HY-12871B